Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype-specific phenotypes
Authors:
- Ipsita G KunduIKIpsita G Kundu
- Nicolas ToroNTNicolas Toro
- Aaron Y MochizukiAMAaron Y Mochizuki
- Jaldeep LanghnojaJLJaldeep Langhnoja
- Rithvik V AyyagariRARithvik V Ayyagari
- James C CronkJCJames C Cronk
- Sarah M ReelSRSarah M Reel
- Luis E Tron EsquedaLELuis E Tron Esqueda
- Pavithra ViswanathPVPavithra Viswanath
- Amy B HeimbergerAHAmy B Heimberger
- 17 September 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
Abstract
Background: Oligodendroglioma is a primary central nervous system tumor classified by the presence of isocitrate dehydrogenase (IDH) mutations and codeletion of 1p/19q. A lack of faithful preclinical model systems for this disease has limited progress in understanding the biology of this genetically unique subtype of adult diffuse-type glioma and in developing new effective therapies. To address this unmet need, we sought to establish a mouse model that faithfully recapitulates the genetic and phenotypic features of human IDH-mutant 1p/19q-codeleted oligodendroglioma. Methods: We performed in utero electroporation to introduce distinct combinations of genetic alterations and evaluated their potential to form tumors. Resulting tumors were characterized by histology, metabolite profiling, RNA-sequencing and single-cell RNA-sequencing. Results: We identified co-expression of IDH1R132H and PIK3CAE545K together with loss of Cic, Fubp1, and Cdkn2a (termed OligoCdkn2a) as the optimal genetic combination to drive fully penetrant tumors that histologically resemble human grade III IDH-mutant 1p/19q-codeleted oligodendroglioma. Substituting Cdkn2a loss with Trp53 deletion decreased latency and shifted tumors toward high-grade astrocytoma histology. OligoCdkn2a tumors displayed metabolic and transcriptional changes associated with IDH and CIC mutations, and single-cell sequencing identified a bias toward oligodendrocyte differentiation compared to an IDH wild-type glioblastoma mouse model. Conclusions: To our knowledge, OligoCdkn2a tumors represent the first autochthonous, genetically engineered mouse model to recapitulate the genetic, histological, and transcriptional features of human IDH-mutant 1p/19q-codeleted oligodendrogliomas. This model will provide a valuable platform to further dissect mechanisms of tumorigenesis and test novel therapeutic strategies for this molecularly distinct glioma subtype.Keywords
Funding Information
- UC Brain Tumor Center and the Holly and David Cook Family Brain Tumor Research Endowment
- National Institutes of Health (CA120813)
- National Institutes of Health (NS120547)
- National Institutes of Health (CA221747)
This publication has 59 references indexed in Scilit:
- Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaCancer Cell, 2024
- De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant gliomaCancer Cell, 2022
- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomasActa Neuropathologica, 2020
- Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early GliomagenesisCancer Cell, 2016
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionCancer Cell, 2015
- Oligodendroglioma: pathology, molecular mechanisms and markersActa Neuropathologica, 2015
- CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomasActa Neuropathologica, 2012
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytomaCancer Cell, 2005